12.12.2018 14:58 - About Us - Mediadaten - Imprint & Contact - succidia AG
Scientist > Prof. Dr. Katharina Schindowski Zimmermann

Prof. Dr. Katharina Schindowski Zimmermann

// studied biochemistry and received her doctorate in 2001 on biomarkers in Alzheimer’s disease

// This was followed by positions at the University of Heidelberg and at Sanofi-Aventis in France

// She led an independent group of researchers at Inserm (Lille, France) until 2007, followed by a position at Boehringer Ingelheim Pharma

// In early 2010, she accepted a professorship in Molecular Pharmacology at Biberach University of Applied Sciences

Contact: laborundmore@succidia.de

How biopharmaceutical drug substances use the nose as a pathway to the brain

Behind the doorman’s back - von Johannes Flamm, Stefan Carle, Martina Stützle, Prof. Dr. Katharina Schindowski Zimmermann

According to WHO estimates, over 1 billion people worldwide suffer from disorders of the central nervous system (CNS). Some of the most familiar are Alzheimer’s, Parkinson’s and multiple sclerosis. Although they have long been the focus of research, effective pharmacotherapies are still unavailable for many of these diseases. What is it about CNS disorders that makes it especially difficult to develop drug products that target pathophysiological...